Suppression of HIV‐1 infection in linomide‐treated SCID‐hu‐PBL mice
暂无分享,去创建一个
C. Martínez-A | L. Boscá | S. Hortelano | P. Lucas | A. Serrano | G. Del Real | M. Llorente | C. Redondo | L. Gómez | J. Torán | Lucio Gómez | G. del Real | Antonio Serrano
[1] C. Raker,et al. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues , 1997, Antimicrobial agents and chemotherapy.
[2] H. Clifford Lane,et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies , 1997, Nature Medicine.
[3] M. Clerici,et al. Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. , 1997, The Journal of infectious diseases.
[4] C. Martínez-A,et al. Linomide administration to mice attenuates the induction of nitric oxide synthase elicited by lipopolysaccharide-activated macrophages and prevents nephritis in MRL/Mp-lpr/lpr mice. , 1997, Journal of immunology.
[5] Justin C. McArthur,et al. Immunologic NO Synthase: Elevation in Severe AIDS Dementia and Induction by HIV-1 gp41 , 1996, Science.
[6] R. Kaempfer,et al. Linomide, an immunomodulator that inhibits Th1 cytokine gene expression. , 1996, International immunology.
[7] C. Martínez-A,et al. Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. , 1996, The Journal of clinical investigation.
[8] John W. Mellors,et al. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.
[9] D. Ho,et al. Viral Counts Count in HIV Infection , 1996, Science.
[10] N. Katopodis,et al. Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[11] J. Merrill,et al. Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha, and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain , 1995, The Journal of experimental medicine.
[12] S. Lipton,et al. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV- associated neurological disease , 1995, The Journal of experimental medicine.
[13] C. Nathan,et al. Regulation of biosynthesis of nitric oxide. , 1994, The Journal of biological chemistry.
[14] C. Johnsson,et al. The immunomodulator LS-2616 (linomide) more effectively than sensitization of the donor enhances graft-versus-host reaction after small bowel transplantation. , 1994, Transplant immunology.
[15] T. Kollmann,et al. Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID- hu mice after peripheral inoculation with HIV-1 , 1994, The Journal of experimental medicine.
[16] U. Testa,et al. gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte‐derived macrophages , 1994, Journal of leukocyte biology.
[17] G. Kroemer,et al. Linomide inhibits programmed cell death of peripheral T cells in vivo , 1994, European journal of immunology.
[18] G. Kroemer,et al. Linomide, a novel immunomodulator that prevents death in four models of septic shock , 1993, European journal of immunology.
[19] G. Nisticó,et al. HIV gp120 glycoprotein stimulates the inducible isoform of no synthase in human cultured astrocytoma cells. , 1993, Biochemical and biophysical research communications.
[20] D. Karussis,et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[21] A. Fauci,et al. Cytokine modulation of HIV expression. , 1993, Seminars in immunology.
[22] C. Nathan,et al. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide , 1993, The Journal of experimental medicine.
[23] J. Merrill,et al. Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1 , 1992, Journal of virology.
[24] B. Simonsson,et al. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. , 1992, Transplantation.
[25] J. McCune,et al. Suppression of HIV infection in AZT-treated SCID-hu mice. , 1990, Science.
[26] C. Maury,et al. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. , 1988, The American journal of medicine.
[27] D. Mosier. Human immunodeficiency virus infection of human cells transplanted to severe combined immunodeficient mice. , 1996, Advances in immunology.
[28] A. Nagler,et al. The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors. , 1996, Leukemia research.
[29] P. López-Jaramillo,et al. The L-arginine: nitric oxide pathway. , 1993, Current opinion in nephrology and hypertension.
[30] C. Nathan,et al. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon-gamma and bacterial lipopolysaccharide. , 1993, Transactions of the Association of American Physicians.
[31] J. Hibbs. Synthesis of nitric oxide from L-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. , 1991, Research in immunology.
[32] A. Fauci,et al. Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. , 1990, Immunology today.